Outcome of ulcer-associated duodenitis after short-term medical treatment

Paoluzi, P.; Pallone, F.; Zaccardelli, E; Ripoli, Florenza Lüder; Marcheggiano, Adriana; Carratù, R.

doi:10.1007/bf01308410

Cited by 10 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, open observations reported that cimetidine cannot influence the endo scopic features of ulcer-independent nonspe cific duodenitis [33], Although cimetidine was found to reduce somehow the severity of histological changes in duodenitis [36] and to decrease the amount of the inflammatory infiltrate [14] and of mucosal cell proliferation [35], the drug failed to prove superior to placebo in influencing the histopathological appearance [46,48],…”

Section: Principles Of Treatmentmentioning

confidence: 97%

“…Others have observed that after medical treatment for peptic ulcer only duodenitis confined to the ulcer area im proved and only in patients with complete reepithelization of the ulcer crater. In con trast, duodenitis located in areas far from the ulcer was not influenced either by the out come of duodenal ulceration or by antiulcer therapy [33].…”

Section: Duodenitis and Duodenal Ulcermentioning

confidence: 99%

“…Ulcer-associated duodenitis can be con sidered as a focal inflammatory reaction which can or cannot improve with ulcer healing [2,33], Treatment o f 'satellite' duo denitis should generally be identified with antiulcer therapy.…”

Section: Principles Of Treatmentmentioning

confidence: 99%

“…Ulcer-associated duodenitis may or may not disappear at the time of ulcer healing [2,33] . According to some authors endoscopicpersistence of moderate or severe duodenitis would represent incomplete control of duo denal ulcer disease and favor ulcer recur rence [2].…”

Section: Duodenitis and Duodenal Ulcermentioning

confidence: 99%

See 3 more Smart Citations

Focus on Duodenitis

Guslandi

1986

Dig Dis

View full text Add to dashboard Cite

Section: Principles Of Treatmentmentioning

confidence: 97%

Section: Duodenitis and Duodenal Ulcermentioning

confidence: 99%

Section: Principles Of Treatmentmentioning

confidence: 99%

Section: Duodenitis and Duodenal Ulcermentioning

confidence: 99%

See 2 more Smart Citations

Focus on Duodenitis

Guslandi

1986

Dig Dis

View full text Add to dashboard Cite

“…For instance, Paoluzzi et al [26] showed that patients with complete healing after treatment of their DU had a 30% recurrence rate at 6 months, whereas patients with incomplete healing showed nearly 80% recurrence in the same period. In our prospective study [18,19] we found that during maintenance treatment with ranitidine, 150 mg, recurrence rates were twice as frequent in patients with erosive duodenitis as in those witli complete healing of all epithelial defects (23 and 12%.…”

Section: Resolving the Recurrence Problemmentioning

confidence: 99%

Treatment of Acid-Related Disorders with Gastric Acid Inhibitors: The State of the Art

1990

Digestion

View full text Add to dashboard Cite

Since their introduction in 1976, and until recently, the H₂-receptor antagonists have been the ‘state-of-the-art’ gastric acid inhibitors, but the advent of omeprazole, the acid pump inhibitor, has necessitated a reassessment of therapy for acid-related diseases. In making this reassessment, the following therapeutic goals should be considered: rapid and reliable therapeutic effect, safety, simple treatment regimen, resolution of recurrence, and cost-effectiveness. Extensive clinical evidence indicates that omeprazole offers an advance over the H₂-receptor antagonists in achieving these goals. A series of meta-analyses shows that omeprazole gives more rapid symptom relief and more reliable healing than the H₂-receptor antagonist, ranitidine, in uncomplicated duodenal ulcer (DU), in uncomplicated gastric ulcer (GU) and in reflux oesophagitis (RO). By contrast with the H₂-receptor antagonists, refractoriness leading to failure to heal is virtually unknown with omeprazole. Omeprazole also fulfils the goal of therapeutic safety, and this has been documented in extensive short- and long-term clinical and laboratory studies. Omeprazole has a simple treatment regimen: 20 mg once daily is recommended in the routine treatment of DU, GU and RO. As a result of its high therapeutic success rate, omeprazole is also cost-effective. Taking all these factors into account, it is concluded that omeprazole approaches the therapeutic targets set for the treatment of acid-related disorders.

show abstract

Basal gastric acid secretion in nonulcer dyspepsia with or without duodenitis

Collen

Loebenberg

1989

Digest Dis Sci

View full text Add to dashboard Cite

Nonulcer dyspepsia with or without duodenitis and duodenal ulcer disease are often considered to be a spectrum of the same acid-peptic process. Some reports evaluating basal gastric acid secretion in nonulcer dyspepsia and duodenal ulcer disease have supported that impression; however, results from different studies have been mixed. In order to compare basal gastric secretory profiles in nonulcer dyspepsia and duodenal ulcer disease, we determined basal acid outputs in 66 consecutive patients with the diagnosis of nonulcer dyspepsia. All patients with nonulcer dyspepsia had at least a three-month history of epigastric abdominal pain, and all had negative upper gastrointestinal endoscopies except for 14 with duodenitis. The 66 patients with nonulcer dyspepsia were compared to 40 asymptomatic normal subjects and 114 patients with endoscopically documented duodenal ulcer disease. There was no significant difference in mean basal acid output among all 66 patients with nonulcer dyspepsia (2.9 +/- 2.7 meq/hr), the group of normal subjects (3.2 +/- 2.7 meq/hr), the 14 patients with nonulcer dyspepsia with duodenitis (3.0 +/- 2.1 meq/hr), and the 52 patients with nonulcer dyspepsia without duodenitis (2.9 +/- 2.9 meq/hr). However, mean basal acid output of the patients with duodenal ulcer disease (9.1 +/- 7.6 meq/hr) was significantly higher than all the other groups (P less than 0.001). The gastric acid secretory profiles determined in this study do not appear to support the view that nonulcer dyspepsia with or without duodenitis and duodenal ulcer disease are a spectrum of the same acid-peptide process.

show abstract

Outcome of ulcer-associated duodenitis after short-term medical treatment

Cited by 10 publications

References 7 publications

Focus on Duodenitis

Focus on Duodenitis

Treatment of Acid-Related Disorders with Gastric Acid Inhibitors: The State of the Art

Basal gastric acid secretion in nonulcer dyspepsia with or without duodenitis

Contact Info

Product

Resources

About